

Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

IVERMECTIN

RECOMMENDATION

There is insufficient evidence to recommend the use of ivermectin in the treatment of patients with mild-to-moderate COVID-19 (Very low quality of evidence; Conditional recommendation)

We suggest against the use of ivermectin for the treatment of patients with severe COVID-19 (Very low quality of evidence; Conditional recommendation)

We suggest against the use of ivermectin combined with doxycycline for the treatment of patients with COVID-19 (Very low quality of evidence; Conditional recommendation)

Consensus Issues

Studies that favored the use of ivermectin for the treatment of COVID-19 were of very low quality, and participants in these studies were given drugs other than ivermectin. The most common adverse events that were observed for ivermectin were gastrointestinal symptoms, headache, dizziness, and nausea. Esophagitis and dyspepsia were observed on the use of ivermectin combined with doxycycline. There is still a need for good quality evidence to show that ivermectin has a significant benefit for the treatment of COVID-19.

Furthermore, health equity may be decreased if budget will be allocated for ivermectin rather than efficacious medications and standard of care. The cost of and availability of human grade ivermectin is a crucial consideration. The registered oral and parenteral preparations of ivermectin were registered for veterinary use only. Only the topical preparation of ivermectin is registered for human use. According to the Philippine Food and Drug Administration, drugs that were registered for veterinary use should not be utilized for human consumption. *NOTE: The Consensus Panel agreed to make separate recommendations for patients with different disease severity. These recommendations were made without considering the dose of ivermectin, which was highly variable across the trials.*

EVIDENCE SUMMARY

Should ivermectin be used in the treatment of patients with COVID-19 infection?

Evidence Reviewers: Marquis Von Angelo Syquio Go Joson, MD; John Jefferson V. Besa, MD; Frangelo Conrad Tampus, MD; Dan Louie Renz O. Tating, RN, MSc (cand.); Howell Henrian G. Bayona, MSc, MSc (cand.)



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Key Findings

Our search yielded 16 randomized controlled trials (RCTs) that evaluated the effect of ivermectin against placebo or standard of care for patients with COVID-19. Eight of these 16 RCTs are preprints. Although we found evidence suggesting that ivermectin may significantly reduce mortality, this effect is still very uncertain due to very low quality of evidence. Downgrading occurred due to serious inconsistency, imprecision, and serious to very serious risk of bias in most of the studies.

Subgroup analysis revealed that the observed mortality benefit was only present for studies that had lower methodological quality, had not yet been peer-reviewed, or used high doses of ivermectin.

Ivermectin did not show any significant effect on virologic clearance at day 6-7, clinical deterioration, need for mechanical ventilation, clinical improvement at day 6-10, clinical deterioration, hospital discharge at day 10-14, duration of hospitalization, and time to complete symptom resolution.

The adverse effects observed from the use of ivermectin were not significantly different from those observed in the control groups. Gastrointestinal symptoms, dizziness, and rash were the most common adverse effects reported in the RCTs. However, significant adverse events (e.g., erosive esophagitis, non-ulcer dyspepsia) was reported in studies that combined ivermectin+doxycycline.

Based on very low certainty of evidence from 3 RCTs that compared ivermectin+doxycycline to placebo/standard of care, ivermectin+doxycycline was favored in terms of clinical improvement on D6-10, clinical deterioration, and time to symptom resolution, but not for virologic clearance or duration of hospitalization. There was no significant mortality benefit.

Introduction

Ivermectin is an anti-helminthic drug repurposed as a potential therapy for COVID-19 because of its anti-viral properties and immunomodulatory effects. In-vitro studies show that ivermectin limits viral infection (e.g. SARS-CoV-2) by preventing viruses from suppressing the host's antiviral response. This action is through the inhibition of the importin alpha/beta-1 nuclear transport proteins that are utilized by viruses to promote infection [1]. As an immunomodulator, ivermectin may reduce cytokine secretion by inhibiting the translocation of nuclear transcription factor K-B and phosphorylation of mitogen activated protein (MAP) kinases.

Among mice exposed to lethal doses of lipopolysaccharide endotoxin, ivermectin was shown to improve survival and was associated with lower levels of tumor necrosis factor alpha, IL-1 and IL-6 inflammatory markers. Currently, it is unknown whether ivermectin can also reduce severity and prevent mortality of COVID-19 when used as therapy [2].

Review Methods

MEDLINE, Cochrane Library, and gray literature in MedRxIV, and BioRxIV (initial search date up to 2 February 2021; updated 7 April 2021) were searched using the following keywords and MeSH terms: "ivermectin", and COVID-19 related terms. Ongoing trials were searched in



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Clinicaltrials.gov and NMA-COVID-19 registry. We also searched for relevant evidence from the NICE Guidance (https://www.nice.org.uk/guidance), COVID-19 Open Living Evidence Synthesis to Inform Decision (<u>https://covid-nma.com/</u>; updated 25 March 2021), National COVID-19 Clinical Evidence Taskforce Living Guidelines (https://covid19evidence.net.au/) and WHO Living CPG. Included studies from systematic reviews on the same topic [22,23,24] were searched as well and included as long as they provided sufficient information to allow critical appraisal.

Observational studies or quasi-randomized trials were excluded. For the outcomes mortality and adverse effects, subgroup analysis was done according to ivermectin dose used and disease severity. We also performed sensitivity analysis to assess the robustness of the results or if the conclusions may be affected from the exclusion of studies with high / serious risk of bias. Separate analyses were done for (1) ivermectin as monotherapy, and (2) ivermectin in combination with doxycycline.

Articles that met the following eligibility criteria were included:

Intervention: Ivermectin as a treatment or adjunct to standard treatment, ivermectin with doxycyline.

Comparator: placebo, any active control (standard of care), or no intervention

Outcomes: mortality, clinical deterioration, need for mechanical ventilation, hospital length of stay, time to clinical improvement, radiologic improvement, virologic clearance by PCR, adverse events.

Study design: randomized controlled trials (RCTs)

Results

Characteristics of included studies

Our initial search on 2 February, 2021 found 218 studies. Removal of duplicates and initial screening yielded 18 studies for full text assessment. 28 articles were excluded because of having a non-randomized controlled trial design, using ivermectin for prophylaxis, or other reasons (see Appendix 3).

As of 30 March 2021, we found 16 randomized controlled trials (RCTs) (N=1,923) that used ivermectin as treatment for adults with COVID-19 in Bangladesh [3,19,21], Spain [4], Pakistan [5,17], Egypt [6], Argentina [7], India [8,9], Iran [10], Turkey [11], Mexico [15], Brazil [18], Colombia [16], Iraq [20]. Sample sizes ranged from 20 to 473. Twelve studies enrolled only mild to moderate cases [3,4,5,7,8,9,16,17,18,19,21], while 3 enrolled only severe cases [6,11,15]. Three included a mix of mild to severe cases [10,6,20], with 1 RCT [10] not specifying the number of patients under each severity group. Ten of the 16 studies (63%) were pre-prints and have not yet been peer-reviewed [6,7,8,9,10,11,15,17,20,21].

Fourteen RCTs compared ivermectin with placebo/standard of care, while 2 RCTs compared ivermectin+doxycyline with placebo/standard of care [20,21]. Different treatment regimens of ivermectin were used: 13 RCTs used low dose ivermectin 200mcg/kg (12mg) [3,5,8-11,15-19, 20-21] and 6 RCTs used high dose ivermectin 400-600mcg/kg [4,6,7,8,10,18]. Duration of ivermectin



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

treatment ranged from 1-5 days. Seven studies were placebo-controlled [3,4,8,9,10,15,16] while 7 used standard of care [5,6,7,11,17,18,19]. Detailed characteristics of the included studies are available in Appendix 1.

Methodological quality

The overall rating for quality of evidence was very low for most of the outcomes; low for hospital discharge at day 10-14, number of symptomatic days, and virologic clearance/negative PCR at day 6-10; moderate for clinical improvement at day 6-10 and mean days to symptom resolution. The quality of evidence was downgraded due to varying degrees of risk of bias in most studies, serious imprecision due to a small number of events and sample sizes as well as wide confidence intervals in the estimates, and/or serious inconsistency in results due to moderate heterogeneity. Risk of bias was rated very serious in 9/16 (56.3%) studies [3,6,9,11,15,18,19,20,21] and serious in 5/16 studies [4,5,7,10,17]. Only 2 trials (Mohan et al., 2020; Lopez-Medina et al., 2021) exhibited no serious risk of bias [8,16].

Summary of results of included studies

*the relevant Forest Plots are found in Appendix 4

Comparison 1: Ivermectin vs. placebo / standard of care

Mortality

Based on 9 RCTs, ivermectin significantly reduced overall mortality among COVID-19 patients (2% for ivermectin vs 7.8% for control) (RR 0.30 [95% CI 0.12, 0.73], n=1,559) (Figure 1.1). However, the certainty of this estimate for this outcome is affected by moderate heterogeneity (I²=56%) across studies and high risk of bias in most (7/9) of the studies. Subgroup analysis was performed to explore if the inconsistency may be explained by differences in disease severity prior to treatment (mild-to-moderate, severe, mixed), ivermectin dosage (high vs. low), study quality (studies with higher vs. lower risk of bias). We observed that the mortality benefit was only present for studies that had lower methodological quality, had not yet been peer-reviewed, or used high doses of ivermectin.

Effect of study quality on mortality

In studies with higher methodological quality, ivermectin did not show any significant mortality benefit (RR 0.24 [95% CI 0.01, 5.87]) [8,16]. In contrast, studies that exhibited serious or very risk of bias issues, a significant effect was noted (RR 0.30 [95%CI 0.12, 0.79], 7 RCTs) [3,4,6,9,10,11,15]. Preprints more clearly favored ivermectin (RR 0.32 [95% CI 0.13, 0.79], 6 RCTs) (Figure 1.2) [4,6,9,10,11,15], compared to studies that have been peer-reviewed (RR 0.24 [95% CI 0.01, 5.87] 3 RCTs) [3,8,16] (Figure 1.3).

Effect of disease severity on mortality

In severe patients, very low quality evidence from 3 pre-print studies [6,11,15] suggested that ivermectin did not significantly reduce mortality in patients with severe COVID-19 (RR 0.42 [95% CI 0.12, 1.43] I^2 =72%, n=333) (Figure 1.4). In the only RCT that reported mortality benefit, a very



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

serious risk of bias was noted due to unclear randomization methods and selection bias from enrolling more patients with ischemic heart disease in the control group 12/100 vs 5/100) [6].

In patients with mild-to-moderate disease, a significant mortality benefit was seen with ivermectin (RR 0.14 [95% CI 0.03,0.79] I²=0%, n=1,009, 6 RCTs) (Figure 1.4). In patients with mixed disease severity, the Iranian RCT by Niaee *et al.* also showed significant reduction in mortality from ivermectin use (RR 0.18 [95% CI 0.06,0.55], n=60) (Figure 1.4) [10]. This study showed serious risk of bias due to unclear blinding of patients and physicians, differences in baseline characteristics in the experimental versus placebo group (i.e., more patients with negative RT-PCR results in placebo). Due to these concerns related to risk of bias as well as serious imprecision, the quality of evidence was downgraded to very low.

Effect of ivermectin dose on mortality

Significant benefit was noted only with high dose (RR 0.08 [95% CI 0.03, 0.27] I²=0%, 4 RCTs, n=591) [Mohan, Chaccour, Niaee, Elgazzar] but *not* with low dose ivermectin (RR 0.55 [95% CI 0.30, 1.00] I²=0%, 7 RCTs, n=931) [Mohan, Ahmed, Ravikirti, Lopez-Medina, Niaee, Okumus, Gonzalez] (Figure 1.5).

Adverse effects

Ivermectin was not associated with increased adverse effects (RR 0.87 [95% CI 0.70, 1.09] I^2 =36%; n=1369; 10 RCTs) (Figure 1.6). Subgroup analysis showed similar findings regardless of dose, with an RR of 0.80 for high dose ([95% CI 0.57, 1.11], I^2 =6, 5 RCTs) and RR of 1.05 for low dose ([95% CI 0.65, 1.69], I^2 =31%, 7 RCTs) (Figure 1.7). A very low GRADE rating was assigned to this body of evidence due to small number of events, imprecision, inconsistency and serious risk of bias in most studies from unclear randomization, allocation and blinding methods.

Gastrointestinal symptoms, dizziness, headache, and rash were the most common side effects reported. One patient in the ivermectin group reported hyponatremia (unspecified degree or serum sodium values) as a serious adverse effect [7]. One high-quality RCT [16] reported serious adverse events (e.g., multi-organ failure) in 4 patients (2/198 in control, 2/200 ivermectin group), but considered these to be unrelated to ivermectin.

Other outcomes

The proportion of patients showing virologic clearance at day 6 to 10 (RR 1.08 [95% CI 0.90, 1.30] I^2 =71%; n=770) (Figure 1.8) was not significantly different based on 9 RCTs [3,4,5,8,9,11,17,18,19].

The effects of ivermectin were not significantly different from control on other outcomes: clinical deterioration (RR 0.66 [95% CI 0.34, 1.26] $I^2=0\%$; n=837) (Figure 1.9) ([3,7,8,9,16], need for mechanical ventilation (RR 0.40 [95% CI 0.06,2.55] $I^2=8\%$; n=309) (Figure 1.10)[7,8,9], clinical improvement at day 6-10 (RR 1.01 [95% CI 0.87,1.16] $I^2=18\%$; n=933) (Figure 1.11) [5,11,9,16], hospital discharge at day 10-14 (RR 1.08 [95% CI 0.97, 1.21] $I^2=0\%$; n=237) (Figure 1.12) [8,9], duration of hospitalization (mean difference (MD) -0.82 [95% CI -3.86, 2.22] $I^2=82\%$) (Figure 1.13) [3,15,10].



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Three RCTs [8,16,19] showed that ivermectin had no effect in shortening the number of days to complete symptom resolution. Based on 1 high quality RCT [16] that enrolled mild-to-moderate patients, the average time to resolution of symptoms was 10 days (IQR, 9-13) in the ivermectin group compared with 12 days (IQR, 9-13) in the placebo group. This difference was not statistically significant (hazard ratio for resolution of symptoms, 1.07 [95%CI, 0.87 to 1.32]; p = .53 by log-rank test). The other two RCTs [8,19] that reported mean (SD) data showed a mean difference of -0.56 days (95% CI -1.61, 0.48] (Figure 1.14).

Low quality evidence from 1 RCT showed that ivermectin significantly reduced the number of symptomatic days of mild-moderate cases by 30% (RR 0.70, 95% CI [0.63 to 0.78]; n=577 days reported) [4]. This study had unclear blinding of participants and investigators as well as allocation concealment.

Comparison 2: lvermectin+doxycycline vs. placebo / standard of care

Based on very low quality evidence from 3 RCTs [3,20,21], combining ivermectin with doxycycline did not significantly reduce mortality (RR 0.28 [95% CI 0.07, 1.06] I^2 =0%, n=561) (Figure 2.1). This effect was observed in for both mild-to-moderate patients (RR 0.14 [95% CI 0.01, 2.70) I^2 =0%, 3 RCTs, n=508) and severe patients (RR 0.33 [95% CI 0.08, 1.47], n=53) [20] (Figure 2.2). It also did not significantly affect virologic clearance on day 7-14 (RR 0.87 [95% CI 0.15, 5.08] I^2 =85%, n=409) (Figure 2.3) [3, 21] as well as duration of hospitalization (MD 0.40 [95% CI -1.71, 2.51]) (Figure 2.4) [3].

For clinical outcomes, ivermectin+doxycycline was found to have significant effects in terms of clinical improvement at D6-10 (RR 1.36 [95% CI 1.12, 1.67], n=363) (Figure 2.5) [21], preventing clinical deterioration (RR 0.49 [95% CI 0.28, 0.86], n=409) (Figure 2.6)[3, 21], and shortening time to symptom resolution (MD -7.29 [95% CI -9.31, -5.27]) (Figure 2.7) [20].

Significant harm was found with ivermectin+doxycycline based on 2 RCTs (4.4% vs. 0%; RR 18.7 [95% CI 1.10, 318.75], n=409) (Figure 2.8). Unpublished data from Mahmud (2021) reported 2 serious adverse events (erosive esophagitis) and 7 other adverse events (non-ulcer dyspepsia) only in the ivermectin+doxycycline group.

Recommendations from Other Groups

The US NIH (11 Feb 2021) did not recommend either for or against the use of ivermectin for the treatment of COVID-19 due to insufficient level of evidence [12]. Key limitations identified in studies included a small sample size, varying doses and schedules of ivermectin, potential confounding effect of concomitant medications given to patients, and incomplete description of outcomes and patient characteristics.

The Infectious Diseases Society of America (IDSA) (13 Feb 2021) suggests against the use of ivermectin for outpatient/mild-to-moderate and hospitalized/severe COVID-19 cases unless in the context of a clinical trial (very low certainty of evidence, conditional recommendation) [13]. The IDSA Guidelines were based on 7 RCTs and 2 non-randomized trials.

Likewise, the Australian COVID-19 Living CPG (February 2021) does not recommend the use of ivermectin outside of trials [12-14].



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

The WHO living guideline on COVID-19 therapeutics (31 March 2021) does not recommend to use ivermectin in patients with COVID-19 except in the context of a clinical trial. This recommendation applies to patients with any disease severity, any duration of symptoms.

Research Gaps

As of 30 March 2021, there were at least 73 ongoing clinical trials investigating the efficacy of ivermectin as treatment for COVID-19 based on the COVID-19 NMA database.



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

References

- [1] Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer. Antiviral Res. 2020;177:104760. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32135219.
- [2] Kalfas S, Visvanathan K, Chan K, Drago J. The therapeutic potential of ivermectin for COVID-19: a review of mechanisms and evidence [Internet]. MedRxiv. 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.11.30.20236570v1?rss=1'
- [3] Ahmed S Ross AG, Hossain MS,Clemens JD,Sumiya MK,Phru CS,Rahman M,Zaman K,Somani J,Yasmin R,Hasnat MA,Kabir A,Aziz AB,Khan WA,Karim M M. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International journal of infectious diseases; 2020.
- [4] Chaccour, C., Casellas, A., Blanco-Di Matteo, A., Pineda, I., et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, p.100720; 2021.
- [5] Chachar, K., Rabia, B., Aijaz, Z., Khurshid, A., et al. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. International Journal of Sciences; 2020.
- [6] Elgazzar A, Hany B, Youssef S, Hany B, Hafez M, Moussa H. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. Research Square; 2020.
- [7] Królewiecki, A., Lifschitz, A., Moragas, M., Travacio, M., et al. Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial. SSRN Electronic Journal; 2020.
- [8] Mohan A, Tiwari P, Suri T, Mittal S., et al. Ivermectin in mild and moderate COVID-19 (RIVETCOV): a randomized, placebo-controlled trial. Research Square Preprint. 2021.
- [9] Ravikirti, Ranjini, R., Chandrima, P., et al. Ivermectin as a potential treatment for mild to moderate COVID-19 A double blind randomized placebo-controlled trial. 2021.
- [10] Niaee, M. S., Gheibi, N., Namdar, P., et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial. Research Square; 2020.
- [11] Okumus, N., Demirtürk, N., Çetinkaya, R., et al. The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management. Clinical trials.gov. 2021
- [12] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed 19 March 2021.
- [13] Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Gallagher J, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America 2021; Version 4.1.1. Available at https://www.idsociety.org/practice-guideline/covid-19guideline-treatment-and-management/. Accessed 19 March 2021.
- [14] Australian guidelines for the clinical care of people with COVID-19 Australian National COVID-19 Clinical Evidence Taskforce. Available at https://app.magicapp.org/#/guideline/L4Q5An/rec/ny8MYL. Accessed 19 March 2021.
- [15] Gonzalez JLB, Gamez MG, Enciso EAM, et al. Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial. medRxiv. 23 Feb 2021. Available at doi: <u>https://doi.org/10.1101/2021.02.18.21252037</u>.



- [16] López-Medina E, López P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial [published online ahead of print, 2021 Mar 4]. JAMA. 2021;10.1001/jama.2021.3071. doi:10.1001/jama.2021.3071
- [17] Bukhari SH, Asghar A, Perveen N, Hayat A, Mangat SA, Butt KR, Abdullah M, Fatima T, Mustafa A, Iqbal T. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease. medRxiv. 5 Feb 2021. Available at doi: https://doi.org/10.1101/2021.02.02.21250840
- [18] Pott-Junior H, Paoliello MB, Miguel ADC, Cunha AF, Freire CCM, et al. Use of ivermectin in the treatment of Covid-19: A pilot trial. Toxicology Reports. 2021;<u>https://doi.org/10.1016/j.toxrep.2021.03.003</u>.
- [19] Podder, CS, Chowdhury, N, Sina, MI, Haque, WMMY. Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study. IMC Journal of Medical Science. 14(2): 2020.
- [20] Hashim AH, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv 2020.10.26.20219345; doi: https://doi.org/10.1101/2020.10.26.20219345
- [21] Mahmud R. Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection. 2020. https://clinicaltrials.gov/ct2/show/NCT04523831 (accessed April 2021).
- [22] Bryant A, Lawrie TA, Dowswell T, Fordham E, Mitchell S, Hill S, Tham T. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review and meta-analysis [Preprint]. 18 Mar 2020. 10.21203/rs.3.rs-317485/v1
- [23] <u>https://www.francesoir.fr/sites/francesoir/files/media-icons/bird-proceedings-02-03-2021-v151.pdf</u>
- [24] Castañeda-Sabogal A, Chambergo-Michilot D, Toro-Huamanchumo CJ, Silva-Rengifo C, Gonzales-Zamora J. Outcomes of ivermectin in the treatment of COVID-19: a systematic review and meta-analysis. 27 January 2021. https://doi.org/10.1101/2021.01.26.21250420



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Appendix 1: Characteristics of Included Studies for Ivermectin vs Placebo/Standard of Care

No.	Clinical Trial ID/ Title	Country	Study design	Population	Intervention	Comparator	Outcomes
1	Ahmed 2020 A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Follow up 14 days	Bangladesh	Double blind RCT (N=76) Treatment	Mild COVID-19 Age 18 to 65 years Hospitalized within the last 7 days; with either fever (≥37.5C); cough or sore throat; and diagnosed positive for SARS-CoV-2 by rRT-PCR.	Oral ivermectin, 12 mg once daily for 5 days. [n=22] Oral single dose of ivermectin, 12 mg plus oral doxycycline loading dose of 200mg followed by 100 mg q12 for 4 days [n=23] Low dose ivermectin	Placebo [n=22]	Mortality Clinical deterioration Duration of hospitalization Remission of symptoms Virologic clearance Adverse effects
2	Chaccour 2020 The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot,double- blind, placebo- controlled, randomized clinical trial.	Spain	Double blind RCT (N=24) Treatment	Mild COVID-19 Age 18 to 59 years Outpatient setting. Without comorbidities considered as risk factors to develop severe disease or COVID-19.	Oral ivermectin, 400 mcg/kg, single dose [n= 12] High dose ivermectin	Placebo [n= 12]	Mortality Clinical improvement Virologic clearance: proportion of patients who become negative at day 7 and viral culture Adverse effects
3	Chachar 2020 Effectiveness of Ivermectin in SARS-CoV- 2/COVID-19 Patients Follow up 7 days	Pakistan	Open-label RCT (N=50) Treatment	Mild COVID-19 Age 18 to 75 years excluded severe COVID- 19, with malignancy, chronic kidney disease, and liver cirrhosis	3 dose regimen of oral ivermectin 12mg, then 12 mg after 12 hours and 12 mg after 24 hours. [n=25] Low dose ivermectin	Standard care [n=25] Standard care: conventional symptomatic treatment	Clinical improvement Adverse effects
4	Elgazzar 2020 Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic	Egypt	RCT (N=400) Treatment	Mild-Severe COVID-19 Age 14 to 80 years	Oral ivermectin 400 mcg/kg once daily for 4 days [n=200] High dose ivermectin Group I: mild-moderate COVID-19, IVM [n=100]	Hydroxychloroquine 400 mg on day 1, then 200 mg every 12 hours for 5 days plus standard of care [n=200] Standard care: Azithromycin, paracetamol,Vitamin C,	Mortality Clinical deterioration Clinical improvement Virologic clearance Adverse events



r	T						
	Follow up 25 days				Group II: severe COVID- 19; IVM [n=100]	Lactoferrin, Acetylcysteine Group III: mild- moderate COVID-19, SOC [n=100] Group IV: severe COVID-19; SOC [n=100]	
5	Królewiecki 2020 Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial. Follow up 30 days	Argentina	Single- blind (outcome- assessor) RCT (N=45) Adjunct	Mild-Moderate COVID- 19 Age 18 to 69 years Hospitalized patients not requiring ICU admission excluded patients with poorly controlled comorbidities	Oral ivermectin (600mcg/kg) for 5 days Co-Intervention: Standard care [n=30] High dose ivermectin	Standard care [n=15] Standard care: uncertain	Clinical deterioration Adverse effects
6	Mohan 2021 Ivermectin in mild and moderate COVID-19 (RIVETCOV): a randomized, placebo- controlled trial Follow up 14 days	India	Triple blind RCT (N=157 mITT=125)	Mild-Moderate COVID-19 Age 18 years and older	Oral Ivermectin 12 mg single dose [n=40] Oral Ivermectin 24 mg single dose [n=40] Low dose and high dose ivermectin	Placebo [n=45]	Mortality Clinical deterioration Progression to ventilation Clinical improvement Duration of hospitalization Viral clearance Adverse effects
7	Niaee 2020 Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial Follow up 45 days	Iran	Double blind RCT (N=180) Adjunct	Mild-Severe COVID-19 Age 18 years and older excluded patients who are immunocompromised, pregnant women; have chronic kidney disease; malignancy	Single 1 day low dose oral ivermectin (200mcg/kg) OD Co-intervention: Standard care [n=30] 3 day low dose oral ivermectin (200mcg/kg) OD on D1, D3, and D5 Co-intervention: Standard care [n=30] Single 1 day high dose ivermectin (400mcg/kg) OD Co-intervention: Standard care [n=30]	Placebo [n=30] Standard care [n=30] Standard care: oral hydroxychloroquine (HCQ) 200 mg/kg twice per day as standard regimen and a heparin prophylaxis in combination with supplemental oxygen.	Mortality Duration of hospitalization Clinical improvement



					3 day high dose ivermectin (400, 200, 200mcg/kg), 4 pills in D1, D3, and D5 Co-intervention: Standard care [n=30] Low dose and high dose ivermectin		
8	Okumuş 2021 The Effectiveness and Safety of Ivermectin as add-on Therapy in Severe COVID-19 Management	Turkey	Randomiz ed open label (N=66)	Severe COVID-19 Age 18 years and older	Oral Ivermectin 200 mcg/kg for 5 days [n=30] Co-intervention: Standard care Low dose ivermectin	Standard care [n=30] Standard care: Hydroxychloroquine, favipiravir and azithromycin (HFA) HCQine (2x400mg loading dose followed by 2x200mg, po, 5 days), favipiravir (2x1600mg loading dose followed by 2x600mg maintenance dose, po, total 5 days) and azithromycin (500mg 1st day loading dose, followed by 250mg/day, po, total 5 days) (HFA),	Mortality Clinical improvement Viral clearance D10 Adverse effects
9	Ravikirti 2021 Ivermectin as a potential treatment for mild to moderate COVID-19 – A double blind randomized placebo- controlled trial Follow up 10 days	India	Double blind RCT (N=115) Adjunct	Mild-Moderate COVID- 19 Age 18 years and older	Oral ivermectin 12mg on D1 and D2 Co-intervention: standard care [n=57] Low dose ivermectin	Placebo [n=58] Standard care: Hydroxychloroquine, steroids, enoxaparin, antibiotics, remdesivir, convalescent plasma, tocilizumab	Mortality Clinical deterioration Progression to Ventilation Clinical improvement Viral Clearance
10	Pott-Junior 2021 Use of ivermectin in the treatment of COVID-19: a pilot trial	Brazil	Open-label RCT (N=32)	Mild-severe Age 18 years and older	SOC + Ivermectin a. 100mcg/kg (n=6) b. 200mcg/kg (n=14) c. 400mcg/kg (n=7)	SOC (n=4)	% patients with 2 negative PCR tests w/in 7 days Adverse events
11	Lopez-Medina 2021 Effect of ivermectin on time to resolution of symptoms among adults with mild COVID- 19	Colombia	Double- blind RCT (N=476)	Mild COVID-19 Mean age 37 (range: 28- 49)	Oral ivermectin 300 mcg/kg 5 days (n=238) Low dose ivermectin	Placebo (n=238)	Time to resolution of symptoms (D21); % patients with resolved symptoms % patient with clinical deterioration Fever since randomization Escalation of care



							Deaths
12	Bukhari 2021 Efficacy of ivermectin in COVID-19 patients with mild to moderate disease	Pakistan	Open-label RCT (N=100)	Mild-moderate COVID- 19 15-65 yo	Ivermectin 12 mg single dose at admission (n=50) Low dose Ivermectin	SOC (n=50) SOC includes Vit C 500mg OD, Vit D3 200k IU once weekly, paracetamol 500mg SOS	Viral clearance (days to RT- PCR negativity) Adverse effects
13	Beltran-Gonzalez 2021 Efficacy and safety of ivermectin and hydroxychloroqui ne in patients with severe COVID-19	Mexico	Double- blind RCT (N=106)	Severe COVID-19 Mean age 53	Ivermectin 12 or 18 mg accdg to weight (n=36) HCQ 400 mg BID on D1, 200 mg BID for 4 days (n=33)	Placebo (n=37)	Duration of hospitalization Hospital discharge, n(%) Discharged without respiratory deterioration or death, n(%) Respiratory deterioration or death, n(%)
14	Podder 2020 Outcome of ivermectin treated mild to moderate COVID-19 cases: a single- centre, open- label, randomised controlled study	Bangladesh	Open-label RCT (N=62)	Mild-moderate COVID- 19 Age more than 18 years old	single dose of ivermectin 200 micrograms/kg on the day 1 of randomisation Low dose Ivermectin	symptomatic treatment which included antipyretics, cough suppressants, and capsule doxycycline (100 mg every 12 hours for seven days)	time needed for resolution of fever, cough, shortness of breath time needed for full recovery from all symptoms repeat RT-PCR on day 10



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Appendix 2: Characteristics of Included Studies for Ivermectin + Doxycycline vs Placebo/Standard of Care

No.	Clinical Trial ID/ Title	Country	Study design	Population	Intervention	Comparato r	Outcomes
1	Ahmed 2020	Bangladesh	Double blind RCT	Mild COVID-19	Oral ivermectin, 12 mg once daily for 5 days. [n=22]	Placebo [n=22]	Mortality
	A five day course of ivermectin for the treatment of		(N=76)	Age 18 to 65 years			Clinical deterioration
	COVID-19 may reduce the duration of illness.		Treatment	Hospitalized within the last 7 days;	Oral single dose of ivermectin, 12 mg plus oral doxycycline loading dose of 200mg followed by 100 mg q12 for 4		Duration of hospitalization
				with either fever (≥37.5C); cough or sore	days [n=23]		Remission of
	Follow up 14 days			positive for SARS-CoV-2 by rRT-PCR.	Low dose ivermectin		Virologio
							clearance
							Adverse effects
2	Mahmud 2020	Bangladesh	Double blind RCT	Mild-Moderate COVID- 19	Oral ivermectin 12 mg OD and Doxycycline 100mg/cap BID for 5 days. [n=200]	Placebo [n=200]	Mortality
	Clinical Trial of Ivermectin Plus Doxycycline for	linical Trial of ermectin Plus oxycycline for		Age 18 years and older			Clinical improvement
	the Treatment of Confirmed Covid- 19 Infection		freatment		Low dose ivermectin		Clinical Deterioration
	Follow up 30 days						Virologic Clearance
							Adverse Events
3	Hashim 2020	Iraq	Single blind RCT	Mild-Critical COVID-19	Ivermectin 200ug/kg OD for 2 days and another on D7 (if admitted)	Standard care [n=70]	Mortality
	Controlled randomized clinical trial on		(N=140)		Doxycycline 100mg/cap BID	Acetaminophe	Clinical Deterioration
	using Ivermectin with Doxycycline for		Treatment		for 5-10 days (based on clinical improvement)	Vitamin C 1000mg twice/	



treating COVID-19 patients in Baghdad, Iraq Follow up 56 days		Low dose ivermectin	day, Zinc 75- 125 mg/day, Vitamin D3 5000IU/day, Azithromycin 250mg/day x 5 days, Oxygen therapy/ C-	Mean days to symptomatic resolution
			Azithromycin	
Follow up 56 days			250mg/day x 5	
			days,	
			Oxygen	
			therapy/ C-	
			Pap if needed,	
			Dexamethaso	
			ne 6 mg/day	
			Or Matheological	
			Methylprednis	
			twice per day	
			if needed	
			ii needed	
			, Mechanical	
			ventilation, if	
			needed	



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Appendix 3: Characteristics of Excluded Studies (n=28)

No.	Author, year	Study design	Reason for
	Title		exclusion
	Title		
1	Camprubi 2020	Retrospective cohort (n - 26)	Non-RCT
	Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients		
2	Khan 2020	Retrospective cohort (n = 325)	Non-RCT
	Ivermectin treatment may improve the prognosis of patients with COVID-19		
3	Procter 2020	Prospective cohort (n = 922)	Non-RCT
	Clinical outcomes after early ambulatory multidrug therapy for high risk SARS-CoV-2 (COVID-19) infection		
4	Fonseca 2020	Prospective cohort (n = 717)	Non-RCT
	Risk of hospitalization for Covid-19 outpatients treated with		
	various drug regimens in Brazil: Comparative analysis		
5	Malik 2020	Cross sectional study (n = 1409)	Non-RCT
	Clinical Presentation, Management and In-Hospital Outcome of Healthcare Personnel With COVID-19 Disease		
6	Elalfy 2021	Phase I clinical trial (n = 113)	Non-RCT
	Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19		
7	Lima-Morales 2021	Prospective cohort (n = 768)	Non-RCT
	Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico		
8	Roy 2021	Retrospective cohort (n = 56)	Non-RCT
	Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study		
9	Mondal 2020	Cross-sectional study (n = 305)	Non-RCT
	Socio-demographic, clinical, hospital admission and oxygen requirement characteristics of COVID-19 patients of Bangladesh		
10	Morgenstern 2020	Retrospective cohort (n = 3,099)	Non-RCT
	The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020		
11	Hector 2020	Phase I clinical trial? (n = 167)	Non-RCT
	Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID 19		



12	Chowdhury 2021 A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients	Randomized controlled trial (n = 116)	No placebo or standard of care as control group
13	Espitia-Hernandez 2021 A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19 Patients	Proof-of-concept study (n = 35)	Non-RCT
14	Carvallo 2020 USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR)	Prospective cohort (n = 229)	Non-RCT
15	Cadegiani 2020 Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.		
16	Afsar 2020	Case-control study (n = 95)	Non-RCT
	Ivermectin use associated with reduced duration of COVID-19 febrile illness in a community setting		
17	Chahla 2021 A randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID- 19 in healthcare agents	Randomized controlled trial (n = 234)	Ivermectin as pre- exposure prophylaxis
18	Gorial 2020	Pilot trial with synthetic controlled arm (n = 87)	Non-RCT
	Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)		
19	Soto-Becerra 2020	Retrospective cohort (n = 5683)	Non-RCT
	Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru		
20	Rajter 2020	Retrospective cohort (n = 476)	Non-RCT
	Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019 The Ivermectin in COVID Nineteen Study		
21	Budhiraja 2020	Retrospective cohort (n = 1000)	Non-RCT
	Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience		
22	Behera 2021	Case-control study (n = 117)	lvermectin as prophylaxis



	Role of ivermectin in the prevention of SARSCoV-2 infection among healthcare workers in India: A matched case-control study		
23	Hellwig 2020	Ecological study	Ivermectin as prophylaxis, non- RCT
	A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin		
24	Bernigaud 2020	Retrospective cohort (n = 121)	lvermectin as prophylaxis
	Ivermectin benefit: from scabies to COVID-19, an example of serendipity		
25	Alam 2020	Prospective cohort (n = 118)	lvermectin as prophylaxis, non- RCT
	Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study		
26	Vallejos 2021	Ongoing study	Study protocol only
	Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial		
27	Tanioka 2021	Ecological study	Non-RCT
	Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?		
28	Galan 2021	Randomized controlled trial (n = 168)	No placebo or standard of care as control group
	Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection		



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Appendix 4: GRADE Evidence Profile

Author(s): J Question: Iv Setting: wor Bibliograph	Author(s): Joson MVASG, Bayona HHG, Besa JJV, Tampus FC, Tating DLRO Question: Ivermedin compared to standard of care or placebo as treatment for COVID-19 Setting: worldwide Bibliography:													
			Certainty a	ssessment			Nº of patients		Effec	:t				
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ivermectin	standard of care or placebo as treatment	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance		
Mortality														
9 a	randomised trials	very serious ^b	serious c	not serious	very serious 4	none	17/752 (2.3%)	55/570 (9.6%)	RR 0.30 (0.12 to 0.73)	68 fewer per 1,000 (from 85 fewer to 26 fewer)				
Adverse Eve	ents													
10	randomised trials	serious *	serious ^r	not serious	serious a	none	324/764 (42.4%)	271/605 (44.8%)	RR 0.87 (0.70 to 1.09)	58 fewer per 1,000 (from 134 fewer to 40 more)				
Clinical imp	rovement (follow	up: 6-10 days)												
4	randomised trials	serious h	not serious	not serious	not serious	none	158/310 (51.0%)	155/310 (50.0%)	RR 1.01 (0.87 to 1.16)	5 more per 1,000 (from 65 fewer to 80 more)				
Clinical dete	rioration													
5	randomised trials	serious i	serious i	not serious	serious k	none	16/464 (3.4%)	18/339 (5.3%)	RR 0.66 (0.34 to 1.26)	18 fewer per 1,000 (from 35 fewer to 14 more)				
Need for me	chanical ventilati	on												
3	randomised trials	serious ^I	not serious	not serious	very serious 4	none	2/185 (1.1%)	5/124 (4.0%)	RR 0.40 (0.06 to 2.55)	24 fewer per 1,000 (from 38 fewer to 62 more)				
Virologic cle	arance (negative	RT-PCR) (follow up:	6-10 days)											
9	randomised trials	very serious m	very serious ⁿ	not serious	serious °	none	161/269 (59.9%)	117/223 (52.5%)	RR 1.08 (0.90 to 1.30)	42 more per 1,000 (from 52 fewer to 157 more)				
Hospital dis	charge (follow up	: 10-14 days)												
2	randomised trials	not serious	not serious	not serious	serious #	none	119/135 (88.1%)	81/102 (79.4%)	RR 1.08 (0.97 to 1.21)	64 more per 1,000 (from 24 fewer to 167 more)				



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

			Certainty a	ssessment			№ of patients		Effect			
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Ivermectin standard of care or Relative Absolu placebo as (95% Cl) (95% Cl)		Absolute (95% Cl)	Certainty	Importance	
Time to sym	Time to symptom resolution (in days)											
3	randomised trials	serious P	not serious	not serious	not serious	none	Pooled mean difference for Mohan 2020 and Podder 2020 - 0.56 (95% Cl -1 61.0.48). Lopez-Medina: 10 days (IQR 9-13) remmedin group compared with 12 days (IQR 9- 13) planeted group: Harand Rash OT (195%Cl, 037 h 1 -13), p = 33 by (agr-mark text. MODEFIATE					
Duration of I	Duration of hospitalization (days)											
3	randomised trials	serious 9	serious r	serious *	serious ^I	none	Ahmed: mean duration of hospitalization was 9.6 days, 95% (CI [7.7 to 11.7] for vermectin and 9.7 days, 95% (CI [8.1 to 11.0] for the placebo group. Name: mean range of hospitalization was 5.7 days [IQR 4-10] for ivermectin and 8 days [IQR 6-11] for the control group.					
Number of s	ymptomatic days											
1	randomised trials	very serious •	not serious	not serious	not serious	none	171/282 (60.6%)	255/295 (86.4%)	RR 0.70 (0.63 to 0.78)	259 fewer per 1,000 (from 320 fewer to 190 fewer)		

CI: Confidence interval; RR: Risk ratio; MD: Mean difference

Explanations

a. Okumus 2020 assessed mortality at DE0
b. Serious to very serious risk of bias noted for 7/9 studies. Risk of bias downgraded by 1 level: some concerns regarding adequate randomization, deviations from intended interventions and selection of reported results.
c. Moderate heterogeneity (02 = 56%).
d. Imprecision due to small number of events and vide confidence interval that crosses threshold for benefit and harm.
e. Serious to very serious risk of bias not for studies.
f. Moderate heterogeneity (02 = 56%).
g. Some concern for imprecision due to confidence interval between benefit and harm.
h. Serious to very serious risk of bias over the clinical outcome measured ance the study of Chachar and Okrus are open-table in design.
i. Indued 3 studies with an outcome interval. Some concern for wide confidence interval to 2020, Ravkirt et al. 2020;
Outcome measures were different (ICU admission, Progression of OZ requirement, Need for mechanical ventilation).
k. Some concern for vide confidence interval to al. 2020, Ravkirt et al. 2020;
I. Indued 3 studies with a teast serious ink of bias due to high depo out in the study of Ravkirti.
n. Sisk of bias divers that least serious inks of bias due confidence interval endomization dimissing data, some concerns regarding deviations from intended interventions and selection of reported results. Serious concern for risk of bias due to high drop out in the study of Ravkirti.
n. Sisk of bias for Podder 2020
Outcome measures were different (incluanding and unclean binding of patients and outcome assesses.
P. Very serious risk of bias for Podder 2020
I. No budied across 3 studies
Some concern with how the data was represented among the two studies.
Y. Peavation of hospitalization between the two studies cannot be poded.
U. No budied, Studies with a lay astart and outcome assessors.
P. Very serio





Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Risk of biasRando ment mentAlcaeton concessing and mentSimilar chanceler chanceler bindedCaregivers bindedAssessors bindedIntention-to seriesAdequate rollow-up minPublished' rollow-up minSummaryNot serious Very serious 6Yes Unclear 7 No: 2Yes: 4 Unclear 7 No: 2Yes: 4 Unclear 6 No: 3Yes: 11 Unclear 6 No: 3Yes: 3 Unclear 7 No: 3Yes: 3 Unclear 7 No: 3Yes: 3 Unclear 7 No: 3Yes: 4 Unclear 7 No: 3Yes: 3 No: 6Yes: 4 Unclear 7 No: 3Yes: 9 Unclear 7 No: 3Yes: 8 Unclear 7 No: 3Yes: 9 No: 6Yes: 9 No: 6Yes: 9 No: 6Yes: 9 No: 3Yes: 9 No: 6Yes: 9 No: 6Yes: 9 No: 6Yes: 9 No: 6Yes: 9 No: 6Yes: 9 No: 7Yes: 11 Unclear 7 No: 3Yes: 9 No: 6Yes: 11 No: 6Yes: 9 No: 7Yes: 11 Yes: 11 Unclear 7 No: 7Yes: 11 Yes: 11 Unclear 7 No: 7Yes: 11 Yes: 11 Unclear 7 No: 7Yes: 11 Yes: 11 Unclear 7 No: 7Yes: 11 Yes: 11 No: 3Yes: 9 No: 6Yes: 11 No: 3Yes: 9 No: 6Yes: 11 No: 3Yes: 9 No: 6NoNoNoNoYesNo: 6No:	Appendix 5: Appraisal of Included Studies for Ivermectin vs Placebo/Standard of Care										
Summary Surposes Versious: Serious: 	·	Risk of bias	Rando m assign ment	Allocation concealme nt	Similar baseline characterist ics	Patients blinded	Caregivers blinded	Assessors blinded ¹	Intention-to -treat analysis	Adequate follow-up rate	Published?
1. AhmedSeriousYesUnclearVesYesUnclearNo ³ UnclearNo2. Bukhari*Yery seriousYesUnclearYesNoNoNoNoYesNoYes3. ChaccourSeriousYesVesUnclearUnclearUnclearUnclearYesYesYesYesYesYesYesNo4. ChacharSeriousYesNoYesNoNoNoNoYesYesYesNo5. Elgazzar*Very seriousYesUnclearNoUnclearUnclearUnclearUnclearYesYesYesYes6. Gonzalez*Very seriousYesYesYesYesYesYesYesYesYes7. Królewiecki*SeriousYesYesYesYesYesYesYesYesYes8. Lopez- MedinaNot seriousYesYesYesYesYesYesYesYesYes9. Mohan*Not seriousYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesYesNoNoNoNoYesYesYes11. Okumu\$*SeriousYesNoNoNoNoNoYesNoNoYesNo13. Pott-JuniorSeriousYesYesYesYesYesYesYes	Summary	Not serious: 2 Serious: 6 Very serious: 6	Yes: 11 Uncle ar: 1 No: 0	Yes: 5 Unclear: 7 No: 2	Yes: 8 Unclear: 5 No: 1	Yes: 4 Unclear: 2 No: 8	Yes: 5 Unclear:2 No: 7	Yes: Unclear:6 No:	Yes: 11 Unclear: 0 No: 3	Yes: 9 Unclear: 2 No: 3	Yes: 8 No: 6
2. Bukhari*Very seriousYesUnclearYesNoNoNoYesNoYes3. ChaccourSeriousYesUnclearUnclearYesYesYesYesYesYesNo4. ChacharSeriousYesNoYesNoNoNoNoYesYesNo5. Elgazzar*Very seriousGarUnclearUnclearUnclearUnclearUnclearYesYesYesYes6. Gonzalez*Very seriousYesUnclearUnclearNoUnclearUnclearUnclearYesYesYes7. Królewiecki*SeriousYesYesYesYesYesYesYesYesYes8. Lopez- 9. Mohan*Not seriousYesYesYesYesYesYesYesYesYes9. Mohan*Not seriousYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesYesYesNoNoNoNoYesYesYes11. Okumuş*Very SeriousYesNoYesNoNoNoNoNoYesNoNo13. Pott-JunioVery SeriousYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYesYes <tr <tr="">14. Ravikirit*Very Serio</tr>	1. Ahmed	Serious	Yes	Unclear	Unclear	Yes	Yes	Unclear	No ³	Unclear	No
3. ChaccourSeriousYesUnclearUnclearUnclearUnclearYesYesYesYesYesYesNo4. ChacharSeriousYesNoYesNoNoNoNoYesYesNo5. Elgazzar*Very SeriousUnclearUnclearUnclearUnclearUnclearUnclearUnclearYesYesYesYes6. Gonzalez*Very SeriousYesUnclearUnclearUnclearUnclearUnclearUnclearYesYesYes7. Królewiecki*SeriousYesYesYesYesYesYesYesYesYes8. Lopez- Medina*Not seriousYesYesYesYesYesYesYesYesYes9. Mohan**Not seriousYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesYesNoNoNoUnclearYesYesYes11. Okumuş*Very SeriousYesNoYesNoNoNoNoNoNoYesNo13. Polt-JuniorVery SeriousYesYesYesYesYesYesYesYesYesYesYesYesYes14. Ravikirit*Very SeriousYesYesYesYesYesYesYesYesYesYesYesYes14.	2. Bukhari*	Very serious	Yes	Unclear	Yes	No	No	No	Yes	No	Yes
4. ChachariSeriousYesNoYesNoNoNoYesYesNo5. Elgazzar*Very seriousUnclearUnclearNoUnclearUnclearUnclearUnclearYesYesYesYes6. Gonzalez*Very seriousYesUnclearUnclearUnclearUnclearUnclearUnclearYesYesYesYes7. Królewiecki*SeriousYesYesYesYesYesNoNoNoNoYesYesYes8. Lopez- Medina*Not seriousYesYesYesYesYesYesYesYesYesNo9. Mohan*Not seriousYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesUnclearNoNoUnclearYesYesYesYes11. Okumuş*Very seriousYesNoYesNoNoNoNoNoYesNoYes12. PodderVery seriousYesNoYesNoNoNoNoNoYesNoNo13. Pott-JuniorVery seriousYesYesYesYesYesYesYesYesYesYesYesYes14. Ravikirti*Very seriousYesYesYesYesYesYesYesYesYesYesYesYes <t< td=""><td>3. Chaccour</td><td>Serious</td><td>Yes</td><td>Unclear</td><td>Unclear</td><td>Unclear</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td><td>No</td></t<>	3. Chaccour	Serious	Yes	Unclear	Unclear	Unclear	Yes	Yes	Yes	Yes	No
5. Elgazzar*Very seriousUnclearUnclearNoUnclearUnclearUnclearMesMesMesMesMes6. Gonzalez*Very seriousYesUnclearUnclearUnclearUnclearUnclearUnclearMesMesYesYesYes7. Królewiecki*SeriousYesYesYesYesYesYesYesNoNoNoYesYesYesYes8. Lopez- Medina*Not seriousYesYesYesYesYesYesYesYesYesNo9. Mohan*Not seriousYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesYesYesYesYesYesYesYesYes11. Okumuş*Very seriousYesUnclearYesNoNoNoNoNoYesNo12. PodderVery seriousYesUnclearYesNoNoNoNoNoYesNo13. Pott-JuniorVery seriousYesYesYesYesYesYesYesYesYesYesYesYes14. Ravikirit*Very seriousYesYesYesYesYesYesYesYesYesYesYesYes14. Ravikirit*Very seriousYesYesYesYesYesYesYes	4. Chachar	Serious	Yes	No	Yes	No	No	No	Yes	Yes	No
6. Gonzalez*Yery seriousYesUnclearUnclearNoUnclearUnclearUnclearYesYesYesYes7. Królewiecki*SeriousYesYesYesNoNoNoNoYesNoYes8. Lopez- MedinaNot seriousYesYesYesYesYesYesYesYesYesNo9. Mohan*Not seriousYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesYesYesYesYesYesYesYesYes11. Okumuş*SeriousYesNoYesNoNoNoNoNoYesYes12. PodderVery seriousYesNoYesNoNoNoNoNoYesNo13. Pott-JuniorVery seriousYesYesYesYesYesYesYesYesYesYesYes14. Ravikirti*Very seriousYesYesYesYesYesYesYesYesYesYesYesYes	5. Elgazzar*	Very serious	Uncle ar	Unclear	No	Unclear	Unclear	Unclear	Yes	Yes	Yes
7. Królewiecki*SeriousYesYesYesYesNoNoNoNoYesNoYes8. Lopez- MedinaNot seriousYesYesYesYesYesYesYesYesYesNoYesNo9. Mohan*Not seriousYesYesYesYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesYesYesYesYesYesYesYes11. Okumuş*Very seriousYesUnclearYesNoNoNoUnclearYesYes12. PodderVery seriousYesNoYesNoYesNoNoNoNoNoYesNo13. Pott-JuniorVery seriousYesYesYesYesYesYesYesYesYesYesYes14. Ravikirti*Very seriousYesYesYesYesYesYesYesYesYesYesYes	6. Gonzalez*	Very serious	Yes	Unclear	Unclear	No	Unclear	Unclear	Yes	Yes	Yes
8. Lopez- MedinaNot seriousYesYesYesYesYesUnclearYesYesYesNo9. Mohan*Not seriousYesYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesUnclearNoNoUnclearYesYesYesYes10. Niaee*SeriousYesYesUnclearNoNoUnclearYesYesYes11. Okumuş*Very seriousYesUnclearYesNoNoNoNoYesNoYes12. PodderVery seriousYesUnclearUnclearNoNoNoNoNoYesNo13. Pott-JuniorVery 	7. Królewiecki*	Serious	Yes	Yes	Yes	No	No	No	Yes	No	Yes
9. Mohan*Not seriousYesYesYesYesYesYesYesYesYesYes10. Niaee*SeriousYesYesUnclearNoNoUnclearYesYesYes11. Okumuş*Very seriousYesUnclearYesNoNoNoYesYesYes12. PodderVery seriousYesNoYesNoNoNoNoNoYesNo13. Pott-JuniorVery seriousYesYesYesYesNoNoNoNoYesNo14. Ravikirti*Very seriousYesYesYesYesYesYesYesYesYesYesYes	8. Lopez- Medina	Not serious	Yes	Yes	Yes	Yes	Yes	Unclear	Yes	Yes	No
10. Niaee*SeriousYesYesUnclearNoNoUnclearYesYesYesYes11. Okumuş*Very seriousYesUnclearYesNoNoNoNoYesNoYes12. PodderVery seriousYesNoYesNoNoNoNoNoYesNo13. Pott-JuniorVery seriousYesUnclearUnclearNoNoNoNoYesNo14. Ravikirti*Very 	9. Mohan*	Not serious	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
11. Okumuş*Very seriousYesUnclearYesNoNoNoYesNoYes12. PodderVery seriousYesNoYesNoNoNoNoNoYesNo13. Pott-JuniorVery seriousYesUnclearUnclearNoNoNoNoYesNo14. Ravikirti*Very seriousYesYesYesYesYesYesYesYes	10. Niaee*	Serious	Yes	Yes	Unclear	No	No	Unclear	Yes	Yes	Yes
12. PodderVery seriousYesNoYesNoNoNoNoNoYesNo13. Pott-JuniorVery seriousYesUnclearUnclearNoNoNoYesUnclearNo14. Ravikirti*Very seriousYesYesYesYesYesYesYesYesYes	11. Okumuş*	Very serious	Yes	Unclear	Yes	No	No	No	Yes	No	Yes
13. Pott-JuniorVery seriousYesUnclearUnclearNoNoNoYesUnclearNo14. Ravikirti*Very seriousYesYesYesYesYesYesYesYesYesYes	12. Podder	Very serious	Yes	No	Yes	No	No	No	No	Yes	No
14. Ravikirti* Very serious Yes Yes Yes Yes Yes Yes Yes Yes Yes	13. Pott-Junior	Very serious	Yes	Unclear	Unclear	No	No	No	Yes	Unclear	No
	14. Ravikirti*	Very serious	Yes	Yes	Yes	Yes	Yes	Yes	No ²	Yes	Yes

¹For outcomes of mortality and viral clearance, risk of bias for assessor blinding was rated low as these objective outcomes.

²DHigh rop-out rate ³Used non-ITT data for the Kaplan Meier analysis.



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Appendix 6: Appraisal of Included Studies for Ivermectin + Doxycycline vs Placebo/Standard of Care

	Risk of bias	Random assignment	Allocation concealment	Similar baseline characteristic s	Patients blinded	Caregivers blinded	Assessors blinded	Intention-to -treat analysis	Adequate follow-up rate	Published? (preprints)
Summary	Not serious: 0 Serious: 1 Very serious: 2	Yes: 3 Unclear: 0 No: 0	Yes: 1 Unclear: 1 No: 1	Yes: 0 Unclear: 3 No: 0	Yes: 2 Unclear: 0 No: 1	Yes: 2 Unclear:0 No: 1	Yes: 1 Unclear:1 No: 1	Yes: 2 Unclear: 0 No: 1	Yes: 1 Unclear: 1 No: 1	Yes: 2 No: 0
1. Ahmed	Serious	Yes	Unclear	Unclear	Yes	Yes	Unclear	No	Unclear	No
2. Mahmud*	Very Serious ¹	Yes	Yes	Unclear	Yes	Yes	Yes	Yes	No	Yes
3. Hashim*	Very Serious	No ²	No	Unclear	No	No	No	Yes	Yes	Yes

¹Very serious due to high dropout rate

²Very serious due to some concern with randomization - odd even date methodology and poor methodological quality



Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Appendix 7: Forest Plots

	lverme	ectin	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEFG
Chaccour (1)	0	12	0	12		Not estimable		• ? ? ? • • •
Mohan (preprint) (2)	0	100	0	52		Not estimable		GGGGGGG
Ahmed (3)	0	24	0	24		Not estimable		- ?? - ? - ?
Elgazzar (preprint) (4)	2	100	24	100	17.9%	0.08 [0.02, 0.34]	_	?? \varTheta ? 🔂 😨 ?
Ravikirti (preprint) (5)	0	55	4	57	7.2%	0.12 [0.01, 2.09]		
Niaee (preprint) (6)	4	120	11	60	21.9%	0.18 [0.06, 0.55]		~~
Lopez-Medina (7)	0	275	1	198	6.2%	0.24 [0.01, 5.87]		@@@@@@@ ?
Okumus (preprint) (8)	6	30	9	30	24.7%	0.67 [0.27, 1.64]		♀?♀●●♀ ●
Gonzalez (preprint) (9)	5	36	б	37	22.0%	0.86 [0.29, 2.56]		????
Total (95% CI)		752		570	100.0%	0.30 [0.12, 0.73]	◆	
Total events	17		55					
Heterogeneity: Tau ² = 0.	61; Chi ²	= 11.3	8, df = 5	(P = 0)	.04); 12 =	56%		7
Test for overall effect: Z	= 2.66 (P	9 = 0.0	08)				Favours ivermectin Favours control	0
Footnotes							Risk of bias legend	
(1) IVM 400 mcg/kg (sing	le dose)	vs plac	ebo				(A) Random sequence generation (selection bias)
(2) IVM 24mg single dose	e (arm1) (or 12 m	ng single (dose (a	rm2) vs. j	placebo	(B) Allocation concealment (selection	n bias)
(3) IVM 12 mg 1x/day fo	r 5 days	vs. plac	ebo				(C) Similar baseline characteristics	(selection bias)
(4) Mild to severe: IVM 40	00 mcg/k	g 1x/d	ay (6mg/	tab) +	SOC vs. H	ICQ + SOC	(D) Blinding of participants and per	sonnel (performance
(E) IV(M 1.2 mm v. 2 days	500	n la co h	0.000	(LICO	stanaida .	anavanavin antibiaties	(E) Incomplete outcome data (attriti	an hind)

(5) IVM 12mg x 2 days + SOC; vs. placebo + SOC (HCQ, steroids, enoxaparin, antibiotics,... (E) Incomplete outcome data (attrition bias)

(6) IVM 200mcg/kg to 400mcg/kg (1-3 doses) vs. SOC (HCQ, heparin, O2)

(7) IVM 300 mcg/kg 1x/day for 5 days vs. placebo

(8) IVM 200mcg/kg x 5 days vs. SOC (HCQ, AZT, favipiravir)

(9) IVM 12-18 mg/kg (unspecified duration) vs. placebo

(F) Selective reporting (reporting bias)

(G) Blinding of outcome assessment (detection bias)

Figure 1.1. Forest plots comparing ivermectin and control for the outcome of mortality (overall).

	Iverme	ctin	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEF
1.5.1 Pre-prints (not pe	er-revie	wed)						
Gonzalez (preprint) (1)	5	36	6	37	22.3%	0.86 [0.29, 2.56]		000000
Okumus (preprint) (2)	6	30	9	30	25.6%	0.67 [0.27, 1.64]		
Niaee (preprint) (3)	4	120	11	60	22.2%	0.18 [0.06, 0.55]		
Ravikirti (preprint) (4)	0	55	4	57	6.7%	0.12 [0.01, 2.09]		
Elgazzar (preprint) (5)	2	100	20	100	17.5%	0.10 [0.02, 0.42]		22020
Mohan (preprint) (6)	0	100	0	52		Not estimable		
Subtotal (95% CI)		441		336	94.3%	0.32 [0.13, 0.79]	◆	
Total events	17		50					
Heterogeneity: Tau ² = 0.	60; Chi ²	= 10.0	2, df = 4	(P = 0	.04); I ² =	60%		
Test for overall effect: Z	= 2.47 (P	= 0.0	1)					
1.5.2 Published (peer-n	eviewed)							
Lopez-Medina (7)	0	275	1	198	5.7%	0.24 [0.01, 5.87]		
Chaccour (8)	0	12	0	12		Not estimable		••••••
Ahmed (9)	0	24	0	24		Not estimable		• ? • ? • ? •
Subtotal (95% CI)		311		234	5.7%	0.24 [0.01, 5.87]		
Total events	0		1					
Heterogeneity: Not applic	able							
Test for overall effect: Z	= 0.87 (P	e 0.3	8)					
Total (05% CI)		752		570	100.0%	0 32 (0 14 0 73)		
Total (95% CI)	17	132		370	100.0%	0.52 [0.14, 0.75]		
Lotar events	1/	10.0	>1 • ~ ~ - F	(P) (C)	071-12	E OO/		
Heterogeneity, Tau- = 0.	49; Chi-	= 10.0	8, UI = 0 07)	(P = 0	.07); 1- =	50%	0.005 0.1 1 10 2	00
Test for subgroup differe	= 2.7 I (r	2 0.00	2 41 - 1	0 0	07.12		Favours ivermectin Favours control	
Test for subgroup differe	nces. chi	- = 0.0	s, ui = .	L (P = C	.07), 1- =	0%	Disk of bigs legend	
(1) P(M 12 18 mg/kg (m		durat		acaba			Kisk of bias legend	(relection bins)
(1) IVM 12-18 mg/kg (un	ispecified	OC (HC	O ATT (acebo	4		(A) Random sequence generation	(selection bias)
(2) IVM 200mcg/kg x 5 C	ays vs. 5	00 (10	Q, AZI, I	soc ((CO here)	rin (02)	(B) Allocation concealment (selection	(relaction biss)
(3) IVM 200mcg/kg to 40	socium	11-50	IUSES) VS	(HCO)	tog, nepa	inn, Oz)	(C) Similar baseline characteristics (D) Blinding of participants and pe	(selection bias)
(5) Source patients: D/M	100 mca	ko 1x4	day (6m	(neg)	SOC: IN	HCO + SOC	(E) Incomplete outcome data (attribute)	tion bias)
(6) IVM 24 ma single date	a (arm1)	or 12 m	uay (only	dose (a	m2) vc	neg + Suc	(E) Selective reporting (reporting h	(ac)
(7) IVM 200 mco/ko 1×/	day for 5	dave w	n placeb	ouse (a	1112/ VS.	placebo	(r) selective reporting (reporting b	14.5/
(8) IVM 400 mcg/kg (k)	ale dose)	ve place	abo					
(0) P/M 12 mg 1v/day fo	r E dour	vs piac						

(9) IVM 12 mg 1x/day for 5 days vs. placebo

Figure 1.2. Mortality, subgroup analysis according to publication status



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

	Iverme	ctin	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI	ABCDEF
1.4.1 High quality (No	serious ri	sk of t	olas)					
Lopez-Medina (1)	0	275	1	198	6.2%	0.24 [0.01, 5.87]	·	
Mohan (preprint) (2)	0	100	0	52		Not estimable		
Subtotal (95% CI)		375		250	6.2%	0.24 [0.01, 5.87]		
Total events	0		1					
Heterogeneity: Not appl	icable							
Test for overall effect: Z	= 0.87 (P	= 0.3	8)					
1.4.2 Low quality (serie	ous or ve	y serie	ous risk (of blas)			
Gonzalez (preprint) (3)	5	36	6	37	22.0%	0.86 (0.29, 2.56)		777888
Okumus (preprint) (4)	6	30	9	30	24.8%	0.67 [0.27, 1.64]		
Niaee (preprint) (5)	4	120	11	60	22.0%	0.18 [0.06, 0.55]		
Ravikirti (preprint) (6)	0	55	4	57	7.2%	0.12 [0.01, 2.09]		
Elgazzar (preprint) (7)	2	200	24	200	17.8%	0.08 [0.02, 0.35]		220200
Chaccour (8)	0	12	0	12		Not estimable		
Ahmed (9)	0	24	0	24		Not estimable	·	
Subtotal (95% CI)		477		420	93.8%	0.30 [0.12, 0.79]	•	
Total events	17		54					
Heterogeneity: Tau ² = 0	.73; Chi ²	= 11.2	9, df = 4	(P = 0)	.02); 12 =	65%		
Test for overall effect: Z	= 2.43 (P	= 0.0	21					
Total (95% CI)		852		670	100.0%	0.30 [0.13, 0.73]	•	
Total events	17		55					
Heterogeneity: Tau ² = 0	0.61; Chi ²	= 11.3	2, df = 5	(P = 0)	.05); 12 =	56%	have also do	
Test for overall effect: Z	= 2.66 (P	= 0.0	08)	65.650.08	803/355005		0.005 0.1 1 10	200
Test for subgroup differ	ences: Chi	2 = 0.0)2, df = 1	1 (P = 0)	0.89), I ² =	0%	ravours ivermecun ravours contri	DI
Footnotes							Risk of blas legend	
(1) Low dose, mild-mod	erate						(A) Random sequence generation	(selection blas)
(2) High and low dose, r	nild-mode	rate					(B) Allocation concealment (select	tion bias)
(3) Low dose, severe, ve	ry serious	risk of	bias				(C) Similar baseline characteristic	s (selection bias)
(4) Low dose, severe, ve	ry serious	risk of	bias				(D) Blinding of participants and p	ersonnel
(5) Low and high dose, r	mixed sew	erity, se	erious risk	of bia	S		(E) Incomplete outcome data (attr	rition blas)
(6) Low dose, mild-mod	erate						(F) Selective reporting (reporting	bias)
(7) High dose, mild-mod	derate and	sever	e, very se	rious ri	sk of bias			
(8) High dose, mild-mod	derate, sei	rious ris	sk of blas					
(9) Low dose, mild-mod	lerate, ser	ious ris	k of blas					

Figure 1.3. Mortality, subgroup analysis according to study quality



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

	lverme	ctin	Contr	ol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEF
1.3.1 Mild to moderate								
Lopez-Medina (1)	0	275	1	198	5.1%	0.24 [0.01, 5.87]		
Ravikirti (preprint) (2)	0	55	4	57	6.0%	0.12 [0.01, 2.09]		
Elgazzar (preprint) (3)	0	100	4	100	6.0%	0.11[0.01, 2.04]		220200
Ahmed (4)	0	24	0	24		Not estimable		
Mohan (preprint) (5)	0	100	0	>2		Not estimable		
Subtotal (95% CI)	0	566	0	443	17.1%	0.14 [0.03, 0.79]		
Total events	0	500	0			0.14 [0.03, 0.73]		
Heterogeneity Tau ² = 0	00' Chi ²	- 0.16	df = 2.0	P = 0 4	$933 \cdot 1^2 = 0$	95		
Test for overall effect: Z	= 2.22 (P	= 0.0	, ur – 2 (31		////	29 C		
restron overall encourses. E	elee v		-,					
1.3.2 Severe								
Gonzalez (preprint) (7)	5	36	6	37	21.1%	0.86 [0.29, 2.56]		222999
Okumus (preprint) (8)	6	30	9	30	24.4%	0.67 [0.27, 1.64]		
Elgazzar (preprint) (9)	2	100	20	100	16.4%	0.10 [0.02, 0.42]		2 2 🛛 2 🕒 🖉
Subtotal (95% CI)		166		167	61.9%	0.42 [0.12, 1.43]	-	
Total events	13		35					
Heterogeneity: Tau ² = 0.	82; Chi ²	= 7.06	, df = 2 (P = 0.0	$(33); I^2 = 7$	2%		
Test for overall effect: Z	= 1.39 (P	= 0.1	7)					
1.3.3 Mixed								
Nisee (preprint) (10)	4	120	11	60	21.0%	0 18 (0 06 0 55)		
Subtotal (95% CI)	4	120	**	60	21.0%	0.18 [0.06, 0.55]	-	
Total events	4		11				-	
Heterogeneity. Not applic	able							
Test for overall effect: Z	= 3.03 (P	= 0.0	02)					
Total (95% CI)		852		670	100.0%	0.30 [0.14, 0.66]	◆	
Total events	17		55					
Heterogeneity: $Tau^2 = 0$.	44; Chi²	= 10.8	1, df = 6	(P = 0	.09); l ² =	44%	0.005 0.1 1 10	200
Test for overall effect: Z	= 3.02 (P	= 0.0	03)				Favours ivermectin Favours cont	rol
Test for subgroup differe	nces: Chi	* = 1.4	i3, df = 2	(P = 0).49), I* =	0%	Phile of his stand	
Footnotes							Kisk of blas legend	(coloction bias)
(1) Low dose							(A) Random sequence generation	n (selection bias)
(2) Low dose							(C) Similar baseline characteristi	ics (selection bias)
(4) Low dose							(D) Blinding of participants and	personnel
(5) Low and high dose							(E) Incomplete outcome data (at	trition bias)
(6) High dose							(F) Selective reporting (reporting	bias)
(7) Low dose								
(8) Low dose								
(9) High dose								
(10) Low and high dose								

Figure 1.4. Mortality, subgroup analysis according to disease severity, ivermectin vs. control



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

	lverme	ctin	Contr	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEF
1.2.1 High dose								
Niaee (preprint) (1)	1	60	6	30	10.7%	0.08 [0.01, 0.66]		
Elgazzar (preprint) (2)	2	200	24	200	16.4%	0.08 [0.02, 0.35]	_ _	220200
Mohan (preprint) (3)	0	51	0	26		Not estimable		000000
Chaccour (4)	0	12	0	12		Not estimable		
Subtotal (95% CI)		323		268	27.1%	0.08 [0.03, 0.27]	◆	
Total events	3		30					
Heterogeneity: Tau ² = 0.	00; Chi ²	= 0.00,	, df = 1 (P = 1.0	$(00); ^2 = ($)%		
Test for overall effect: Z	= 4.14 (P	< 0.0	001)					
1.2.2 Low dose								
Gonzalez (preprint) (5)	5	36	6	37	20.5%	0.86 [0.29, 2.56]		222999
Okumus (preprint) (6)	6	30	9	30	23.1%	0.67 [0.27, 1.64]		• 7 • • • •
Niaee (preprint) (7)	3	60	5	30	17.1%	0.30 [0.08, 1.17]		••?•••
Lopez-Medina (8)	Ó	275	1	198	5.6%	0.24 [0.01, 5.87]		
Ravikirti (preprint) (9)	0	55	4	57	6.6%	0.12 [0.01, 2.09]		
Ahmed (10)	0	24	0	24		Not estimable		• 7 • 7 •
Mohan (preprint) (11)	0	49	0	26		Not estimable		
Subtotal (95% CI)		529		402	72.9%	0.55 [0.30, 1.00]	-	
Total events	14		25					
Heterogeneity. Tau ^e = 0.	00; Chi*	= 3.03	, df = 4 (P = 0.5	5); l* = (3%		
Test for overall effect: 2	= 1.95 (P	= 0.03	51					
Total (95% CI)		852		670	100.0%	0.29 [0.13, 0.67]		
Total events	17		55			0.25 [0.25] 0.07]	•	
Heterogeneity Tau ² = 0	57: Chi2	= 12.0	6 df = 6	(P = 0	061: 12 =	5.0%		-
Test for overall effect: Z	= 2.88 (P	= 0.0	04) 04)	ų – v		2000	0.005 0.1 1 10 20	00
Test for subaroup differe	nces: Chi	2 = 7.9	1. df = 1	(P = 0).0051. J ²	= 87.4%	Favours ivermectin Favours control	
Footnotes			.,				Risk of bias legend	
(1) Mixed							(A) Random sequence generation (selection bias)
(2) Severe							(B) Allocation concealment (selectio	n bias)
(3) Mild-moderate							(C) Similar baseline characteristics	(selection bias)
(4) Mild-moderate							(D) Blinding of participants and per	rsonnel
(5) Severe							(E) Incomplete outcome data (attriti	ion bias)
(6) Severe							(F) Selective reporting (reporting bi	as)
(7) Mixed								
(8) Mild-moderate								
(9) Mild-moderate								
(10) Mild-moderate								
(11) Mild-moderate								

Figure 1.5. Mortality, subgroup analysis according to dose

	lverme	ctin	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI A I	CDEFG
Bukhari (preprint) (1)	0	41	0	45	en reennet F	Not estimable	91	
Pott-Junior (2)	7	27	2	4	3.3%	0.52 [0.16, 1.67]		20200
Ahmed (3)	13	24	19	24	16.5%	0.68 [0.45, 1.04]		29292
Elgazzar (preprint) (4)	48	200	70	200	22.7%	0.69 [0.50, 0.94]	20	2002
Lopez-Medina (5)	211	275	161	198	38.2%	0.94 [0.86, 1.04]		00007
Chaccour (6)	5	12	5	12	4.8%	1.00 [0.39, 2.58]		22666
Mohan (preprint) (7)	14	100	6	52	5.3%	1.21 [0.50, 2.97]		
Krolewiecki (preprint) (8)	13	30	5	15	6.1%	1.30 [0.57, 2.96]	-+	
Okumus (preprint) (9)	5	30	3	30	2.6%	1.67 [0.44, 6.36]		
Chachar (10)	8	25	0	25	0.6%	17.00 [1.03, 279.53]		
Total (95% CI)		764		605	100.0%	0.87 [0.70, 1.09]	•	
Total events	324		271				0050	
Heterogeneity: Tau ² = 0.0	3; Chi ² =	12.54	df = 8 (P = 0.1	3); 1 ² = 3	6%	steere also also also	
Test for overall effect: Z =	1.20 (P -	0.23)			10		wermectin less harmful wermectin more harmful	
Footnotes							Risk of bias legend	
(1) Low dose, mild-moder	ate						(A) Random sequence generation (selection blas)	
(2) Low and high dose, mil	d-modera	ate					(B) Allocation concealment (selection blas)	
(3) Low dose, mild-moder	ate						(C) Similar baseline characteristics (selection bias)	
(4) High dose, mild-mode	rate and s	evere					(D) Blinding of participants and personnel (performance	bias)
(5) Low dose, mild-moder	ate						(E) Incomplete outcome data (attrition blas)	
(6) High dose, mild-mode	rate						(F) Selective reporting (reporting bias)	
(7) Low and high dose, mil	d-modera	ate					(G) Blinding of outcome assessment (detection bias)	
(8) High dose, mild-model	rate							
(9) Low dose, severe								
(10) Low dose, mild-mode	rate							

Figure 1.6. Adverse effects of ivermectin compared to placebo (overall).



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI A	BCDEFG
1.7.1 High dose	
Okumus (preprint) (1) 5 30 3 30 2.4% 1.67 [0.44, 6.36]	2999999
Krolewiecki (preprint) (2) 13 30 5 15 5.9% 1.30 [0.57, 2.96]	
Mohan (preprint) (3) 6 51 3 26 2.5% 1.02 [0.28, 3.75]	
Elgazzar (preprint) (4) 48 200 70 200 25.8% 0.69 [0.50, 0.94] -	20200
Pott-Junior (5) 1 7 1 2 0.8% 0.29 [0.03, 2.80]	22020
Subtotal (95% CI) 318 273 37.3% 0.80 [0.57, 1.11]	
Total events 73 82	
Heterogeneity: Tau ² = 0.01; Chi ² = 4.27, df = 4 (P = 0.37); l ² = 6%	
Test for overall effect: Z = 1.33 (P = 0.18)	
1.7.2 Low dose	
Chachar (6) 8 25 0 25 0.6% 17.00 [1.03, 279,53]	
Mohan (preprint) (7) 8 49 3 26 2.7% 1.41 [0.41, 4.88]	
Charcour (8) 5 12 5 12 4.5% 1.00 [0.39, 2.58]	
Lopez-Medina (9) 211 2/5 161 198 53.0% 0.94 [0.86, 1.04]	
Pott-junior (10) 6 20 1 2 1.8% 0.60 [0.13, 2.80]	
Anmed (11) 0 24 0 24 Not estimable	
Buiktran (preprint) (12) 0 41 0 45 Not estimation	
100 devents 230 $170Homosphir Tau2 = 0.10; (b)^2 = 5.77; df = 4.02 = 0.223; b^2 = 219;$	
Heterogenery, raw = 0.10, Cir = 5.77, Gi = 4 ($r = 0.22$), $r = 5.16$ Test for workel address 7 = 0.10, Q = 0.95)	
1 = 51 + 101 = 0.001 = 10.001 = 0.001	
Total (95% CI) 764 605 100.0% 0.91 [0.74, 1.12]	
Total events 311 252	
Heterogeneity. Tau ² = 0.02; Chi ² = 11.11, df = 9 (P = 0.27); l ² = 19%	
Test for overall effect: Z = 0.88 (P = 0.38)	
Test for subgroup differences: Chi ² = 0.81, df = 1 (P = 0.37), l ² = 0%	
Footnotes. Risk of bias legend	
(1) Severe (A) Random sequence generation (selection bias)	
(2) Mid-moderate (B) Allocation concealment (selection bias)	
(3) Mid-moderate (C) Similar baseline characteristics (selection bias)	
(4) Mild to severe (D) Blinding of participants and personnel (performance	ce bias)
(5) Mid-moderate (E) Incomplete outcome data (attrition bias)	
(6) Mild-moderate (F) Selective reporting (reporting bias)	
(7) Mild-moderate (G) Blinding of outcome assessment (detection bias)	
(8) Mild-moderate	
(9) Mild-moderate	
(10) Mild-moderate	
(11) Mild-moderate	
(12) Mid-moderate	

Figure 1.7. Adverse effects of ivermectin compared to placebo, subgroup analysis according to dose.



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

	Iverme	ctin	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEFG
1.15.1 Mild patients								
Chaccour	12	12	12	12	20.6%	1.00 [0.86, 1.17]	1 +	9222999
Chachar	25	25	25	25	23.0%	1.00 [0.93, 1.08]	•	
Bukhari (preprint)	20	41	18	45	9.3%	1.22 [0.76, 1.96]	1	
Ahmed	13	24	4	24	3.2%	3.25 [1.24, 8.55]	i	9229292
Subtotal (95% CI)		102		106	56.0%	1.19 [0.81, 1.74]	•	
Total events	70		59				19.22	
Heterogeneity: Tau2 =	0.11; Cł	$ni^2 = 35$	5.49, df	= 3 (P -	< 0.0000	1); $l^2 = 92\%$		
Test for overall effect	Z = 0.88	B(P = 0)).38)					
1.15.2 Mixed patient	ts							
Pott-Junior	17	27	2	3	3.9%	0.94 (0.40, 2.21)	1	
Podder	18	20	19	20	19.6%	0.95 [0.79, 1.13]		
Ravikirti (preprint)	13	32	18	44	7.7%	0.99 [0.57, 1.72]		
Mohan (preprint)	29	72	16	42	9.2%	1.06 (0.66, 1.70)		0000000
Okumus (preprint)	14	16	3	8	3.5%	2.33 [0.94, 5.82]	· · · · ·	
Subtotal (95% CI)		167		117	44.0%	1.03 [0.81, 1.29]	i 🔶 👘	Contraction of the second second
Total events	91		58					
Heterogeneity: Tau2 =	0.02; Ch	ni² = 5.	12, df =	4(P =	0.27); 12	= 22%		
Test for overall effect	Z = 0.22	P = 0).83)	1.11011.111	1990/1990/19			
Total (95% CI)		269		223	100.0%	1.08 [0.90, 1.30]	ı 🔶	
Total events	161		117					
Heterogeneity: Tau ² =	0.04; Ch	$ni^2 = 22$	7.69, df	= 8 (P -	0.0005); $l^2 = 71\%$		4
Test for overall effect:	Z = 0.82	? (P = 0	0.41)	CH020708		5 (10 mm 1637) (1	0.10.2 0.5 1 2 5 10	1
Test for subgroup diff	ferences:	Chi2 =	0.41, df	= 1 (P	= 0.52),	$l^2 = 0.06$	Payours ivermecuni Payours control	
Risk of bias legend								
(A) Random sequence	e generati	on (sele	ction bia	s)				
(B) Allocation conceal	ment (sele	ction b	las)	20				
(C) Similar baseline ch	haracterist	tics (sel	ection bi	15)				
(D) Blinding of particip	pants and	person	nel (perf	ormano	e bias)			
(E) Incomplete outcom	ne data (a	ttrition	bias)		2072338			
(F) Selective reporting	(reporting	g bias)						

(G) Blinding of outcome assessment (detection bias)

Figure 1.8. Virologic clearance (PCR negativity on D6-10), ivermectin vs. control

	lverme	ectin	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEFG
Ahmed	0	24	0	24		Not estimable		99999
Lopez-Medina	5	275	7	198	32.7%	0.51 [0.17, 1.60]	· -•+	
Mohan (preprint)	5	80	5	45	30.0%	0.56 [0.17, 1.84]	· -•+	
Ravikirti (preprint)	5	55	6	57	33.1%	0.86 [0.28, 2.67]	·	
Krolewiecki (preprint)	1	30	0	15	4.3%	1.55 [0.07, 35.89]		9999997
Total (95% CI)		464		339	100.0%	0.66 [0.34, 1.26]	•	
Total events	16		18					
Heterogeneity: Tau ² = (0.00; Chi	² = 0.7	6, df = 3	(P = 0	.86); 2 =	0%		
Test for overall effect: 2	= 1.27	(P = 0.3	20)				Favours ivermectin Favours control	
Risk of bias legend								

(A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias)

(C) Similar baseline characteristics (selection bias)

(D) Blinding of participants and personnel (performance bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Blinding of outcome assessment (detection bias)

Figure 1.9. Clinical deterioration, ivermectin vs. control



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD



(C) Similar baseline characteristics (selection bias) (D) Blinding of participants and personnel (performance bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Blinding of outcome assessment (detection bias)

Figure 1.10. Need for Mechanical ventilation, ivermectin vs. control

	Iverme	ctin	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEFG
Ravikirti (preprint)	46	55	51	57	53.4%	0.93 [0.81, 1.08]	+	0000000
Lopez-Medina	74	200	73	198	24.9%	1.00 [0.78, 1.30]	-+-	0000007
Chachar	16	25	15	25	10.0%	1.07 [0.69, 1.65]	_ _	
Okumus (preprint)	22	30	16	30	11.7%	1.38 [0.92, 2.05]	+	•?••••
Total (95% CI)		310		310	100.0%	1.01 [0.87, 1.16]	•	
Total events	158		155					
Heterogeneity: Tau ² =	0.00; Cł	ni ² = 3.	68, df =	3 (P =	0.30); I²	= 18%		7
Test for overall effect:	Z = 0.12	? (P = 0	0.91)				Favours ivermectin Favours control	~

Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Similar baseline characteristics (selection bias)

(D) Blinding of participants and personnel (performance bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Blinding of outcome assessment (detection bias)

Figure 1.11. Clinical improvement on day 6-10, ivermectin vs. control



Risk of bias legend

(A) Random sequence generation (selection bias)

(B) Allocation concealment (selection bias)

(C) Similar baseline characteristics (selection bias)

(D) Blinding of participants and personnel (performance bias)

(E) Incomplete outcome data (attrition bias)

(F) Selective reporting (reporting bias)

(G) Blinding of outcome assessment (detection bias)

Figure 1.12. Hospital discharge at day 10-14



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD



(G) Blinding of outcome assessment (detection bias)

Figure 1.13 Duration of hospitalization, ivermectin vs. control

	lve	rmecti	n	c	ontrol			Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI	ABCDEFG
Lopez-Medina (1)	10	0	200	12	0	198	5	Not estimable	2	0000002
Mohan (preprint)	4.26	2.65	40	4.58	2.94	45	77.6%	-0.32 [-1.51, 0.87]		
Podder	10.09	3.24	32	11.5	5.32	30	22.4%	-1.41 [-3.62, 0.80]		
Total (95% CI)			72			75	100.0%	-0.56 [-1.61, 0.48]	•	
Heterogeneity: Tau2 -	0.00; C	hi ² = (0.72, d	f = 1 (P	= 0.3	9); 12 =	0%		the total total	
Test for overall effect	Z = 1.0	6 (P =	0.29)						Favours Ivermectin Favours control	ol
Footnotes									Risk of bias legend	
1) hazard ratio for re	solution	of sym	ptoms,	1.07 [5	5%CI,	0.87 to	1.32]; p	= .53 by log-rank tes	st(A) Random sequence generation	(selection bias)
									(B) Allocation concealment (select	tion blas)
									(C) Similar baseline characteristic	s (selection bias)
									(D) Blinding of participants and p	ersonnel (performance
									(E) Incomplete outcome data (attr	rition bias)
									(F) Selective reporting (reporting)	bias)

(G) Blinding of outcome assessment (detection blas)

Figure 1.14 Time to symptom resolution (ivermectin vs. control)



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

	IVM+D	OXY	Cont	rol		Risk Ratio	Risk Ratio	Risk of Bias		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEFG		
2.1.1 Mild to modera	ate						8			
Ahmed	0	48	0	48		Not estimable		9 7 7 9 7 9 7		
Hashim	0	23	0	23		Not estimable				
Mahmud	0	183	3	180	20.2%	0.14 [0.01, 2.70]	• • • •			
Subtotal (95% CI)		254		251	20.2%	0.14 [0.01, 2.70]				
Total events	0		3							
Heterogeneity. Not ap	plicable									
Test for overall effect:	Z = 1.30	O(P = 0)	.19)							
2.1.2 Severe										
Hashim	2	22	6	22	79.8%	0.33 [0.08, 1.47]				
Subtotal (95% CI)		22		22	79.8%	0.33 [0.08, 1.47]				
Total events	2		6							
Heterogeneity: Not ap	plicable									
Test for overall effect:	Z = 1.45	(P = 0)	.15)							
Total (95% CI)		276		273	100.0%	0.28 [0.07, 1.06]	-			
Total events	2		9							
Heterogeneity: Tau ² =	= 0.00; Ch	$ni^2 = 0.2$	27, df =	1 (P =	0.60); l ² :	= 0%		ł		
Test for overall effect:	Z = 1.88	B(P = 0	.06)				Eavours iver+doxy Eavours control			
Test for subgroup differences: $Chi^2 = 0.26$, $df = 1$ (P = 0.61), $l^2 = 0\%$										
Risk of bias legend										
(A) Random sequence	e generatio	on (sele	ction bias	5)						
(B) Allocation conceal	ment (sele	ction bi	as)							
(C) Similar baseline ch	naracterist	ics (sele	ection bia	IS)						
(D) Blinding of particip	pants and	person	nel (perfi	ormanc	e bias)					
(E) Incomplete outcom	ne data (at	ttrition b	oias)							
(F) Selective reporting (reporting bias)										
(G) Blinding of outcome assessment (detection bias)										

Figure 2.1. Forest plots comparing ivermectin + doxycycline vs control for the outcome of mortality (overall)



Figure 2.2. Mortality, subgroup analysis according to disease severity, ivermectin+doxycycline vs. control



Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

	IVM + I	Dox	Contr	lo		Risk Ratio	Risk Ratio	Risk of Bias
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl	ABCDEFG
Mahmud (preprint) (1)	14	183	36	180	54.6%	0.38 [0.21, 0.68]		
Ahmed (2)	7	23	3	23	45.4%	2.33 [0.69, 7.93]		• • ? ? • ? • ?
Total (95% CI)		206		203	100.0%	0.87 [0.15, 5.08]		
Total events	21		39					
Heterogeneity: Tau ² = 1.40; Chi ² = 6.85, df = 1 (P = 0.009 Test for overall effect: Z = 0.16 (P = 0.88) <u>Footnotes</u> (1) Day 14 (2) Day 7							Favours IVM + Dox Favours control <u>Risk of bias legend</u> (A) Random sequence generation (B) Allocation concealment (selectii (C) Similar baseline characteristics (D) Blinding of participants and per (E) Incomplete outcome data (attriti	(selection bias) on bias) ; (selection bias) sonnel (performance bias) on bias)

Figure 2.3. Virologic clearance (PCR negativity on D7-14), ivermectin+doxycycline vs. control



Figure 2.4. Duration of hospitalization, ivermectin+doxycycline vs. control

	IVM+DOXY		Control		Risk Ratio		Risk Ratio	Risk of Bias		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	ABCDEFG		
Mahmud	111	183	80	180	100.0%	1.36 [1.12, 1.67]		 		
Total (95% CI)		183		180	100.0%	1.36 [1.12, 1.67]	•			
Total events	111		80							
Heterogeneity. Not applicable										
Test for overall effect: $Z = 3.04$ (P = 0.002)										
							Favours control Favours IVM+DC			
Risk of bias legend										
(A) Random sequence	generatio	on (sele	ction bia	5)						
(R) Allocation concealment (election bias)										
(C) Similar baseline (bereath) (selection bias)										
(c) Blinding of participants and personal (performance bias)										
(b) Information of participants and personnel (personnaice bias)										
(c) incomplete outcome data (attration bias)										
(r) believe reporting (reporting bias)										

(G) Blinding of outcome assessment (detection bias)





Institute of Clinical Epidemiology, National Institutes of Health, UP Manila In cooperation with the Philippine Society for Microbiology and Infectious Diseases Funded by the DOH AHEAD Program through the PCHRD

	IVM + Dox		Control			Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI	
2.9.1 Clinical deterior	ration							
Ahmed	0	23	0	23		Not estimable	_	
Mahmud (preprint) Subtotal (95% CI)	16	183 206	32	180 203	100.0% 100.0%	0.49 [0.28, 0.86] 0.49 [0.28, 0.86]		
Total events	16		32					
Heterogeneity: Not applicable								
Test for overall effect: Z = 2.47 (P = 0.01)								
Total (95% CI)		206		203	100.0%	0.49 [0.28, 0.86]	-	
Total events	16		32					
Heterogeneity: Not ap Test for overall effect: Test for subgroup diff	plicable Z = 2.47 erences:	(P = 0.0 Not ap;)1) plicable				0.1 0.2 0.5 1 2 5 10 Favours IVM + Dox Favours control	

Figure 2.6. Clinical deterioration, ivermectin+doxycycline vs. control



Figure 2.7. Time to symptom resolution (ivermectin+doxycycline vs control)



